We read with interest the article by Kurian et al1 describing a young woman with opsoclonus-myoclonus syndrome (OMS) in the context of an anti–N-methyl-D-aspartate receptor (NMDAR) encephalitis. The clinical signs at presentation were speech difficulties, hypophonia, anxiety, and tremulous eye and head movement followed by increasing gait instability. She was diagnosed with depression and initially hospitalized in the psychiatric division.